Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F.
Ann Hematol. 2022 May;101(5):963-978. doi: 10.1007/s00277-022-04786-y. Epub 2022 Feb 24.
Markers of refractory primary immune thrombocytopenia.
Moulis G, Garabet L.
Br J Haematol. 2023 Oct;203(1):112-118. doi: 10.1111/bjh.19076. Epub 2023 Aug 30.
Refractory immune thrombocytopenia in adults: Towards a new definition.
Arnold DM, Clerici B, Ilicheva E, Ghanima W.
Br J Haematol. 2023 Oct;203(1):23-27. doi: 10.1111/bjh.19075. Epub 2023 Aug 29.
Novel therapeutics and future directions for refractory immune thrombocytopenia.
Al-Samkari H, Neufeld EJ.
Br J Haematol. 2023 Oct;203(1):65-78. doi: 10.1111/bjh.19078.
Pediatric refractory immune thrombocytopenia: A systematic review.
Ibrahim L, Dong SX, O'Hearn K, Grimes AB, Kaicker S, FritchLilla S, Breakey VR, Grace RF, Lebensburger JD, Klaassen RJ, Lambert M.
Pediatr Blood Cancer. 2023 Mar;70(3):e30173. doi: 10.1002/pbc.30173. Epub 2022 Dec 29.
Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP.
Rüfer A, Terrell DR.
Br J Haematol. 2023 Oct;203(1):79-85. doi: 10.1111/bjh.19068.
Thrombocytopenia in pregnancy.
Pishko AM, Marshall AL.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):303-311. doi: 10.1182/hematology.2022000375.
The role of genetics in refractory immune thrombocytopenia.
Zehnder JL, Bussel JB, Cooper N.
Br J Haematol. 2023 Oct;203(1):62-64. doi: 10.1111/bjh.19110.
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.
Miltiadous O, Hou M, Bussel JB.
Blood. 2020 Feb 13;135(7):472-490. doi: 10.1182/blood.2019003599.
Pathogenesis of refractory ITP: Overview.
Cines DB.
Br J Haematol. 2023 Oct;203(1):10-16. doi: 10.1111/bjh.19083.
